Clostridium leptum as Next Generation Probiotics
Background C. leptum and Diseases Services Products Brochures FAQs Resources
Introduction of C. leptum
Clostridium leptum (C. leptum) is one of the three dominant bacteria in the human gut. It has been linked to a variety of diseases. Creative Biolabs is an outstanding, independent USA company offering quality live biotherapeutic product (LBP) related products and first-class customer service to leading pharma, biotech, contract research organizations and universities worldwide. We have deep experience in strain development.
Introduction of C. leptum
The C. leptum group of bacteria is one of the dominant groups of fecal bacteria in adult humans, constituting 16-25% of the fecal microbiota. Among human faecal bacteria, many members of the C. leptum subgroup are fibrolytic and butyrate producing microorganisms thereby contributing to processes important to colonic health. C. leptum subgroup represented 22% of the total faecal bacteria and co dominated with members of Clostridium coccoides group. Members of the C. leptum subgroup are thought to be highly oxygen-sensitive anaerobic bacteria. In adult mice, it maintains the intestinal microecological balance, promotes immune maturation, and increases Treg numbers to alleviate airway inflammation.
C. leptum for Disease Treatment
Adult BABL/C mice were injected with ovalbumin to induce asthma, followed by oral C. leptum or vehicle for 2 weeks. The results showed that oral feeding with C. leptum increased the percentage and the total number of regulatory T cells (Tregs) in the spleens and mediastinal lymph nodes at 14 days after inoculation and attenuated allergen-induced airway hyperresponsiveness and inflammation by inhibiting inflammatory cytokine production but enhancing interleukin 10 and transforming growth factor 1 production in the lungs. C. leptum can attenuate induced allergic airway inflammation in adult mice. Therefore, the findings may provide a new basis for the design of novel probiotic therapies for the treatment of asthma.
Alterations in the fecal bacterial flora occur in IBD. The diversity study of C. leptum group in IBD patients, provides important information regarding the colonic microbiota in IBD. Studies have shown that in ulcerative colitis (UC) and Crohn's disease (CD), both the absolute number of C. leptum groups and the species per individual are reduced. C. leptum (Clostridium clusters IV) appears to be a plausible factor associated with UC. This loss of diversity may affect gut health, even if it's not the main phenomenon that causes intestinal inflammation. Ingestion of prebiotic substrates such as inulin can increase bifidobacteria and F. prausnitzii in the human gut, which may be a possible intervention to treat patients with IBD. Treatment of butyric-producing bacteria such as C. leptum group in IBD patients may be an alternative treatment option for these patients.
Fig.1 Role of the gut microbiota in the pathogenesis of UC.1
What Services Can We Provide for C. leptum at Creative Biolabs?
C. leptum Related Products at Creative Biolabs
We supply a variety of C. leptum strains of different preservation numbers as below. If you need other strains, please contact us.
|
CAT
|
Product Name
|
Product Overview
|
Price
|
|
LBST-064FG
|
Clostridium leptum
|
C. leptum is an anaerobe, mesophilic bacterium that was isolated from human faeces. It is a bacterium species in the genus Clostridium.
|
Inquiry
|
|
LBSX-0522-GF23
|
Clostridium leptum; 29065
|
C. leptum was isolated from human faeces. It is a bacterium species in the genus Clostridium.
|
Inquiry
|
Brochures
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
Creative Biolabs offers technical expertise and experience to provide traceable, customizable LBP development solutions. We have been selected by our large pharmaceutical and biotechnology clients for our flexibility, professionalism, high-cost performance, and fast turnaround time. If you are interested in our C. leptum related products and services, please contact us for more information.
FAQs
How is C. leptum different from other commonly used probiotics?
C. leptum differs from other probiotics like Lactobacillus and Bifidobacterium in its ability to produce butyrate, a potent SCFA. Butyrate not only serves as an energy source for colonocytes but also has anti-inflammatory properties and helps strengthen the intestinal barrier. Moreover, C. leptum's ability to induce Tregs makes it unique in its immunomodulatory effects.
What are the industrial applications of C. leptum as a next-generation probiotic?
C. leptum is being explored for various industrial applications, particularly in the pharmaceutical and food industries. It is used in the development of novel therapeutic approaches for gut health, including treatments for Clostridium difficile infections (CDI) and inflammatory bowel diseases (IBD). Companies are also investigating its use in synthetic microbial communities for fecal microbiota transplantation (FMT) alternatives.
What methodologies are used in the research and development of C. leptum as a next-generation probiotic?
Research methodologies for developing C. leptum as a next-generation probiotic include next-generation sequencing (NGS) to analyze its genomic properties, in vitro fermentation studies to understand its metabolic activities, and in vivo animal models to assess its health benefits and safety. Additionally, real-time quantitative PCR and other molecular techniques are used to quantify and monitor its presence in the gut microbiota.
How does the C. leptum probiotics discovery service support the development of targeted therapies?
The C. leptum probiotics discovery service provides comprehensive genomic and functional analysis to identify strains with the highest therapeutic potential. This service includes advanced next-generation sequencing, in vitro and in vivo assays, and metabolic profiling. By leveraging these tools, researchers can develop targeted probiotic therapies tailored to specific health conditions, ensuring maximum efficacy and safety.
Resources
Reference
-
Zhang, Sai-Long, Shu-Na Wang, and Chao-Yu Miao. "Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention." Frontiers in immunology 8 (2017): 1674. Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
